1-2 of 2
Maria Brown
Close
Sort by
Journal Articles

Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat

John M. Pagel, MD PhD, Megan Othus, PhD, Guillermo Garcia-Manero, MD, Min Fang, Jerald P. Radich, MD, David A. Rizzieri, MD, Guido Marcucci, MD, Stephen A. Strickland, Mark Litzow, MD, Mary Lynn Savoie, MD FRCPC, Stephen R. Spellman, MBS, Dennis L. Confer, MD, Jeffrey Chell, MD, Maria Brown, Bruno C. Medeiros, MD, Mikkael A. Sekeres, MD MS, Tara L. Lin, Geoffrey L. Uy, MD, Bayard L Powell, MD, Jonathan E. Kolitz, MD, Richard A. Larson, MD, Richard M. Stone, MD, David F. Claxton, MD, James Essell, MD, Selina Luger, MD, Sanjay R. Mohan, MD, Anna Moseley, Harry P. Erba, MD PhD, Frederick R. Appelbaum, MD
Journal: Blood
Blood (2016) 128 (22): 1166.
https://doi.org/10.1182/blood.V128.22.1166.1166
Published: 2016
Journal Articles

Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy

Mary Eapen, John P. Klein, Annalisa Ruggeri, Stephen Spellman, Stephanie J. Lee, Claudio Anasetti, William Arcese, Juliet N. Barker, Lee Ann Baxter-Lowe, Maria Brown, Marcelo A. Fernandez-Vina, John Freeman, Wensheng He, Anna Paola Iori, Mary M. Horowitz, Franco Locatelli, Susana Marino, Martin Maiers, Gerard Michel, Guillermo F. Sanz, Eliane Gluckman, Vanderson Rocha
Journal: Blood
Blood (2014) 123 (1): 133–140.
https://doi.org/10.1182/blood-2013-05-506253
Published: 2014
Includes: Supplemental data